[go: up one dir, main page]

HK1034261A1 - Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate - Google Patents

Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate

Info

Publication number
HK1034261A1
HK1034261A1 HK01104903A HK01104903A HK1034261A1 HK 1034261 A1 HK1034261 A1 HK 1034261A1 HK 01104903 A HK01104903 A HK 01104903A HK 01104903 A HK01104903 A HK 01104903A HK 1034261 A1 HK1034261 A1 HK 1034261A1
Authority
HK
Hong Kong
Prior art keywords
propylcarbamate
phosphonooxy
aminophenyl
furanyl
tetrahydro
Prior art date
Application number
HK01104903A
Other languages
English (en)
Inventor
Ian Gordon Armitage
Andrew David Searle
Hardev Singh
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1034261A1 publication Critical patent/HK1034261A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01104903A 1998-07-18 2001-07-13 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate HK1034261A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound
PCT/EP1999/004991 WO2000004033A1 (en) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Publications (1)

Publication Number Publication Date
HK1034261A1 true HK1034261A1 (en) 2001-10-19

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01104903A HK1034261A1 (en) 1998-07-18 2001-07-13 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate

Country Status (48)

Country Link
US (3) US6514953B1 (xx)
EP (2) EP1098898B1 (xx)
JP (1) JP3437553B2 (xx)
KR (1) KR100694721B1 (xx)
CN (1) CN1188422C (xx)
AP (1) AP2001002039A0 (xx)
AR (1) AR019388A1 (xx)
AT (1) ATE229964T1 (xx)
AU (1) AU766056B2 (xx)
BG (1) BG105253A (xx)
BR (1) BRPI9912156B8 (xx)
CA (1) CA2337857C (xx)
CO (1) CO5090836A1 (xx)
CZ (1) CZ300447B6 (xx)
DE (1) DE69904600T2 (xx)
DK (1) DK1098898T3 (xx)
DZ (1) DZ2845A1 (xx)
EA (1) EA003191B1 (xx)
EE (1) EE200100038A (xx)
ES (1) ES2189450T3 (xx)
GB (1) GB9815567D0 (xx)
GC (1) GC0000105A (xx)
GE (1) GEP20033030B (xx)
GT (1) GT199900111A (xx)
HK (1) HK1034261A1 (xx)
HR (1) HRP20010046A2 (xx)
HU (1) HU229700B1 (xx)
ID (1) ID28070A (xx)
IL (1) IL140824A (xx)
IS (1) IS5808A (xx)
JO (1) JO2114B1 (xx)
MA (1) MA26660A1 (xx)
MY (1) MY122323A (xx)
NO (1) NO329676B1 (xx)
NZ (1) NZ509291A (xx)
OA (1) OA11706A (xx)
PA (1) PA8477801A1 (xx)
PE (1) PE20000869A1 (xx)
PL (1) PL195736B1 (xx)
PT (1) PT1098898E (xx)
SK (1) SK285311B6 (xx)
SV (1) SV1999000096A (xx)
TN (1) TNSN99145A1 (xx)
TR (1) TR200100111T2 (xx)
TW (1) TWI245770B (xx)
WO (1) WO2000004033A1 (xx)
YU (1) YU3401A (xx)
ZA (1) ZA200100417B (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
DK1222192T3 (da) * 1999-10-06 2008-10-20 Tibotec Pharm Ltd Hexahydrofuro-2,3-b furan-3-yl-N-3-(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino-1-benzyl-2-hydroxypropyl-carbamat som retroviral proteaseinhibitor
EP1226138B1 (en) * 1999-10-08 2004-12-29 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US7049310B2 (en) * 2001-04-06 2006-05-23 Affinium Pharmaceuticals, Inc. Fab I inhibitors
JP2005523922A (ja) 2002-04-26 2005-08-11 ギリアード サイエンシーズ, インコーポレイテッド 非ヌクレオシド逆転写酵素阻害剤
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
CA2522845A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv
EP1680512A1 (en) 2003-10-24 2006-07-19 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
KR20060127906A (ko) 2003-12-22 2006-12-13 길리애드 사이언시즈, 인코포레이티드 4'-치환된 카보버와 아바카비어 유도체 및 hiv와 hcv항바이러스 활성을 갖는 관련 화합물
DK1828167T3 (da) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
ES2341120T3 (es) 2004-11-26 2010-06-15 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ, インク. Fabi阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
CN102816111B (zh) 2007-03-12 2014-08-06 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
ES2393962T3 (es) 2008-07-08 2013-01-03 Gilead Sciences, Inc. Sales de compuestos inhibidores del VIH.
CA2998344C (en) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
EP2432788A1 (en) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
EP2448949A1 (en) * 2009-06-30 2012-05-09 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
EP2477996A1 (en) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
WO2011085130A1 (en) * 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
DK3127542T3 (en) 2010-01-27 2018-11-12 Viiv Healthcare Co ANTIVIRAL THERAPY
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
WO2011158259A1 (en) * 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
WO2012048043A1 (en) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
WO2013105118A1 (en) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
AU2015353703B2 (en) 2014-11-24 2021-04-01 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス, インコーポレイテッド L-オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも1つと組み合わせて用いる筋肉喪失の治療および予防
MY189221A (en) 2016-02-26 2022-01-31 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス, インコーポレイテッド L-オルニチンフェニルアセテートを製造する方法
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
SK9672000A3 (en) * 1997-12-24 2001-04-09 Vertex Pharmaceuticals Inc Ver Prodrugs of aspartyl protease inhibitors
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
WO2000025784A1 (en) * 1998-11-04 2000-05-11 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ES2295068T3 (es) * 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.

Also Published As

Publication number Publication date
GEP20033030B (en) 2003-07-25
DE69904600T2 (de) 2003-11-13
GC0000105A (en) 2005-06-29
SK762001A3 (en) 2001-10-08
EP1240903A2 (en) 2002-09-18
GT199900111A (es) 2001-01-05
ID28070A (id) 2001-05-03
AR019388A1 (es) 2002-02-13
TNSN99145A1 (fr) 2005-11-10
GB9815567D0 (en) 1998-09-16
NO20010282D0 (no) 2001-01-17
NZ509291A (en) 2003-05-30
YU3401A (sh) 2005-06-10
SK285311B6 (sk) 2006-10-05
JP3437553B2 (ja) 2003-08-18
EP1098898B1 (en) 2002-12-18
BRPI9912156B1 (pt) 2016-07-26
ZA200100417B (en) 2002-02-27
IL140824A (en) 2004-09-27
US20030100537A1 (en) 2003-05-29
DZ2845A1 (fr) 2003-12-01
NO329676B1 (no) 2010-11-29
EP1098898A1 (en) 2001-05-16
US6514953B1 (en) 2003-02-04
JO2114B1 (en) 2000-05-21
HU229700B1 (en) 2014-05-28
MY122323A (en) 2006-04-29
PL345620A1 (en) 2002-01-02
EA003191B1 (ru) 2003-02-27
EA200100053A1 (ru) 2001-08-27
CN1324363A (zh) 2001-11-28
CO5090836A1 (es) 2001-10-30
KR100694721B1 (ko) 2007-03-15
ES2189450T3 (es) 2003-07-01
IL140824A0 (en) 2002-02-10
EE200100038A (et) 2002-06-17
AP2001002039A0 (en) 2001-03-31
PL195736B1 (pl) 2007-10-31
EP1240903A3 (en) 2003-02-12
ATE229964T1 (de) 2003-01-15
NO20010282L (no) 2001-03-07
AU766056B2 (en) 2003-10-09
MA26660A1 (fr) 2004-12-20
US20030096795A1 (en) 2003-05-22
BR9912156A (pt) 2001-04-10
DE69904600D1 (de) 2003-01-30
PT1098898E (pt) 2003-04-30
HUP0103432A3 (en) 2003-01-28
CA2337857A1 (en) 2000-01-27
WO2000004033A1 (en) 2000-01-27
CZ300447B6 (cs) 2009-05-20
IS5808A (is) 2001-01-12
SV1999000096A (es) 2000-07-06
CN1188422C (zh) 2005-02-09
CZ2001219A3 (cs) 2001-07-11
BG105253A (en) 2001-12-29
AU5037999A (en) 2000-02-07
PA8477801A1 (es) 2000-05-24
HUP0103432A2 (hu) 2002-04-29
OA11706A (en) 2005-01-13
DK1098898T3 (da) 2003-04-07
JP2003521447A (ja) 2003-07-15
CA2337857C (en) 2011-01-25
PE20000869A1 (es) 2000-09-08
KR20010071952A (ko) 2001-07-31
TR200100111T2 (tr) 2002-02-21
TWI245770B (en) 2005-12-21
HRP20010046A2 (en) 2002-02-28
BRPI9912156B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PL345620A1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate
ZA986338B (en) Simethicone/anhydrous calcium phosphate compositions.
HK1025580A1 (en) Calcium phosphopeptide complexes
AU3034299A (en) Serine peptidase modulators
AU7252098A (en) Surgical instrument
AU7145098A (en) Surgical instrument
HK1019338A1 (en) Phosphonic acid-substituted benzazepinone-n-aceticacid derivatives, and processes for their prepara tion and pharmaceuticals comprising these compounds.
ZA996648B (en) Novel proteins from actinobacillus pleuropneumoniae.
BR9603540A (pt) n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida
AU5818100A (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate
AU3468199A (en) Sulfur dioxide abatement system
SI1098898T1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
HUP0102237A3 (en) Method for preparing 2-nitro-5-(phenylthio)-anilines
AU1126300A (en) Hydrophilic somatostatin analogs
AUPP265298A0 (en) Simulated illumination of planar, two dimensional shapes
AU3716599A (en) Odometer
TW335892U (en) Measuring device for feather curves, arch degrees
AU9784798A (en) Flexible band reciprocating shaker
HN1999000113A (es) (3s) tetrahidro - 3 - funaril (15, 2r) - 3 - [[4 - aminofenil) sulfonil)] (isobutil) amino] - 1 - bencil - 2 (fosfonooxi) propilcarbamato de calcio.
AU4377999A (en) Hydrogel body
ITBO980069A0 (it) Piattaforma rotante per autoveicoli.
SE9802165D0 (sv) Visarinstrument för fordon
IL126956A0 (en) Bone velocity determination
AU2000222537A1 (en) Intramedullary reference datum instrument for bone resection
AU5080499A (en) Human calcium regulatory proteins

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20190714